The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study

Original research
by
Morford, Kenneth L. et al

Release Date

2022

Geography

USA

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.

Findings/Key points

Benzodiazepine exposure at intake was not observed to impact 12-month treatment retention or duration. These findings support U.S. Food and Drug Administration (FDA) recommendations to not withhold medications for opioid use disorder from patients taking benzodiazepines.

Design/methods

Retrospective cohort study of 2968 patients

doi.org

Keywords

Substitution/OAT
Clinical guidance